<unk> , sold under the brand name Tegsedi, is a 2'-O-(2-methoxyethyl) (2'-MOE) antisense oligonucleotide medication used for the treatment of nerve damage in adults with hereditary transthyretin-mediated amyloidosis. The sequence is TCTTG GTTACATGAA ATCCC, where C is methylated C, and the first and third section (bases 1-5 and 16-20, separated from the middle section by spaces) are MOE-modified. The most common side effects are injection site reactions (redness, swelling, bleeding, pain, rash, and itching at the injection site), nausea, headache, tiredness, low platelet counts, and fever.<unk>  can cause serious side effects, including low platelet counts and kidney inflammation. Because of these serious side effects,<unk>  is available in the United States only through a restricted program called the Tegsedi Risk Evaluation and Mitigation (REMS) Program. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Inotersen
Nusinersen
Belinostat
Riluzole
Calaspargase pegol
Ozanimod
Memantine
Siponimod